Tag: PAA

FightMND Motor Neurone Disease Monepantel PharmAust ASX PAA

PharmAust receives grant from FightMND for monepantel phase one trial in motor neuron disease

Motor neurone disease (MND) charity FightMND has awarded oncology company PharmAust (ASX: PAA) a grant for a Phase 1 trial to examine the effects of its flagship drug candidate monepantel on the disea...
PharmAust ASX PAA monepantel 2020 anti cancer drug Epichem

PharmAust lays out market strategy for lead drug monepantel

Oncology company PharmAust (ASX: PAA) has provided a timely update to the market concerning developments of its lead drug candidate, monepantel (MPL). PharmAust is currently progressing the drug in...
PharmAust ASX PAA monepantel anti-viral potential fight against COVID-19video

PharmAust confirms monepantel’s anti-viral potential in fight against COVID-19

Determined to become one of the first companies to develop an active treatment for COVID-19, oncology company PharmAust (ASX: PAA) has reported it has successfully repeated a second round of in-vitro ...
PharmAust ASX PAA Epichem waste fuels technology Obsidian Minerals

PharmAust subsidiary Epichem signs JV to develop waste-to-fuels technology

PharmAust (ASX: PAA) subsidiary Epichem has entered into a 50:50 joint venture agreement with Western Australia-based private company Obsidian Minerals to develop a novel and disruptive waste-to-fuels...
PharmAust ASX PAA monepantel MPL cancer COVID-19

PharmAust trims losses as monepantel drug development progresses

Oncology company PharmAust (ASX: PAA) has narrowed its losses for the full year as it celebrated many achievements in the overall development of its lead cancer drug, monepantel (MPL). MPL is a vet...
PharmAust ASX PAA SARS-CoV-2 Monepantel Human Respiratory Calu-3 cells in vitro

PharmAust research shows monepantel can inhibit progression of SARS-CoV-2 virus

Preliminary research findings on PharmAust’s (ASX: PAA) lead candidates monepantel and monepantel sulfone have demonstrated that application of the drugs on human respiratory cells can inhibit the pro...
PharmAust clinical trials monepantel COVID-19 canines cancer ASX PAA

PharmAust clinical trials show monepantel fights COVID-19 infectivity, improves prognosis for canines with cancer

Clinical stage oncology company PharmAust (ASX: PAA) has attributed a successful June quarter performance to lead drug monepantel and monepantel sulfone which has shown “remarkable” early results agai...
PharmAust ASX PAA cancer drug monepantel COVID-19

Repeat experiment proves PharmAust’s lead cancer drug can reduce infectivity of COVID-19 cells

A repeat preliminary evaluation of PharmAust’s (ASX: PAA) lead cancer drug monepantel and monepantel sulfone has found it can reduce transmission in cells infected with the current SARS-CoV-2 strain o...
PharmAust ASX PAA study lead cancer drug could suppress COVID-19 infectivity SARS-CoV-2

Studies show PharmAust’s lead cancer drug could suppress COVID-19 infectivity

Preliminary clinical work by PharmAust (ASX: PAA) on the effects of its lead candidate monepantel and monepantel sulfone on cells infected with COVID-19 has demonstrated potential suppression of the v...
PharmAust ASX PAA Monepantel trial anti-cancer treat anive B cell lymphoma MPL tablet pet dog

PharmAust makes progress towards next clinical trial of monepantel

Oncology company PharmAust (ASX: PAA) came out of a trading halt this morning with news that its monepantel canine trial achieved a “successful outcome” with phase 3 trials already on the horizon. ...
PharmAust ASX PAA University of Melbourne U-Vet Werribee Animal Hospital Phase 2 clinical trial monepantel cancer

PharmAust and U-Vet gear up for Phase 2 clinical trial of leading drug candidate monepantel

Oncology company PharmAust (ASX: PAA) is on the home straight to commencing a milestone drug trial following the finalisation of contractual arrangements for its Phase 2 canine cancer trial, to be com...
PharmAust ASX PAA Monepantel tablets Phase 1 dogs

PharmAust reports positive results from phase I anti-cancer tablet trial on dogs

Clinical-stage oncology company PharmAust (ASX: PAA) has received early positive results from a phase I trial of its reformulated monepantel anti-cancer tablets. The canine-based trial commenced la...
PharmAust ASX PAA monepantel clinical trials humans canine dog anti-cancer tablet

PharmAust to begin anti-cancer tablet trials in dogs this month

Oncology company PharmAust (ASX: PAA) has manufactured its first batch of monepantel anti-cancer tablets in readiness for the phase I clinical trial in dogs, which will begin later this month. The ...
PharmAust ASX PAA principal metabolite anti cancer properties monepantel

PharmAust’s principal metabolite confirmed to have anti-cancer properties

Oncology company PharmAust (ASX: PAA) has revealed positive news in relation to its ongoing development of monepantel, with the company confirming that monepantel’s major metabolite has exhibited anti...
PharmAust ASX PAA upscale cancer drug candidate Monepantel Syngene International

PharmAust readies to upscale its flagship cancer drug candidate Monepantel

Clinical-stage oncology company PharmAust (ASX: PAA) could be set to upscale development of its flagship drug candidate ‘Monepantel’, a cancer drug that is potentially both applicable to humans as wel...
PharmAust ASX PAA treat cancer dogs oncology

PharmAust targets unique market for treating cancer in dogs

Australian vets and dog-lovers could soon have an additional weapon in their toolkit to treat cancer in dogs, courtesy of a novel therapy to be developed by oncology company PharmAust’s (ASX: PAA) who...
PharmAust ASX PAA secures US patent cancer drugs

PharmAust secures US patent for cancer drugs

PharmAust (ASX: PAA) has locked in a US patent for its aminoacetonitrile compound drug portfolio, which have anti-cancer properties. “Allowance of this patent secures PharmAust’s ownership for over...